Helga Sanner1, Ivar Sjaastad2, Berit Flatø3. 1. Section of Rheumatology, Norwegian Competence Center of Pediatric and Adolescent Rheumatology, Oslo University Hospital-Rikshospitalet, Institute for Experimental Medical Research, Department of Cardiology, Oslo University Hospital-Ullevål and Institute for Clinical Medicine, Medical Faculty, University of Oslo, Norway.Section of Rheumatology, Norwegian Competence Center of Pediatric and Adolescent Rheumatology, Oslo University Hospital-Rikshospitalet, Institute for Experimental Medical Research, Department of Cardiology, Oslo University Hospital-Ullevål and Institute for Clinical Medicine, Medical Faculty, University of Oslo, Norway. helga.sanner@medisin.uio.no. 2. Section of Rheumatology, Norwegian Competence Center of Pediatric and Adolescent Rheumatology, Oslo University Hospital-Rikshospitalet, Institute for Experimental Medical Research, Department of Cardiology, Oslo University Hospital-Ullevål and Institute for Clinical Medicine, Medical Faculty, University of Oslo, Norway.Section of Rheumatology, Norwegian Competence Center of Pediatric and Adolescent Rheumatology, Oslo University Hospital-Rikshospitalet, Institute for Experimental Medical Research, Department of Cardiology, Oslo University Hospital-Ullevål and Institute for Clinical Medicine, Medical Faculty, University of Oslo, Norway.Section of Rheumatology, Norwegian Competence Center of Pediatric and Adolescent Rheumatology, Oslo University Hospital-Rikshospitalet, Institute for Experimental Medical Research, Department of Cardiology, Oslo University Hospital-Ullevål and Institute for Clinical Medicine, Medical Faculty, University of Oslo, Norway. 3. Section of Rheumatology, Norwegian Competence Center of Pediatric and Adolescent Rheumatology, Oslo University Hospital-Rikshospitalet, Institute for Experimental Medical Research, Department of Cardiology, Oslo University Hospital-Ullevål and Institute for Clinical Medicine, Medical Faculty, University of Oslo, Norway.Section of Rheumatology, Norwegian Competence Center of Pediatric and Adolescent Rheumatology, Oslo University Hospital-Rikshospitalet, Institute for Experimental Medical Research, Department of Cardiology, Oslo University Hospital-Ullevål and Institute for Clinical Medicine, Medical Faculty, University of Oslo, Norway.
Abstract
OBJECTIVES: The aims of this study were to examine disease activity by the Paediatric Rheumatology International Trials Organization (PRINTO) criteria for inactive disease and the Myositis Disease Activity Assessment Tool (MDAAT) in JDM patients after long-term follow-up and to identify predictors of these outcomes. METHODS: A retrospective inception cohort of 59 patients diagnosed with JDM was clinically examined in a cross-sectional study a median of 16.8 years (range 2.0-38.1) after symptom onset. Patients were divided by the PRINTO criteria into clinically inactive and active disease. Disease activity was also measured by MDAAT and other validated tools. Medical records were reviewed for early disease variables and medication. RESULTS: By the PRINTO criteria, 31/59 (51%) patients were active and 29/59 (49%) were inactive. By MDAAT, 43/59 (73%) of the patients had measurable disease activity, most commonly found in the skin (59%) and skeletal (27%) systems. MDAAT showed moderate to strong correlations with other disease activity measures (rsp 0.39-0.87, P < 0.05) except for muscle enzymes. Active patients had higher disease activity than inactive patients measured by MDAAT (P < 0.001) and other disease characteristics (all P ≤ 0.002) except for patients' global assessment of disease activity. After controlling for gender and follow-up time, calcinosis during disease-course predicted high MDAAT, age<9 years at diagnosis predicted active disease and organ damage present 6-12 months post diagnosis predicted both outcomes. CONCLUSION: After 16.8 years, 51-73% of JDM patients had active disease. Disease activity by the PRINTO criteria and MDAAT were moderately to highly associated with most other disease characteristics and was predicted by early damage.
OBJECTIVES: The aims of this study were to examine disease activity by the Paediatric Rheumatology International Trials Organization (PRINTO) criteria for inactive disease and the Myositis Disease Activity Assessment Tool (MDAAT) in JDM patients after long-term follow-up and to identify predictors of these outcomes. METHODS: A retrospective inception cohort of 59 patients diagnosed with JDM was clinically examined in a cross-sectional study a median of 16.8 years (range 2.0-38.1) after symptom onset. Patients were divided by the PRINTO criteria into clinically inactive and active disease. Disease activity was also measured by MDAAT and other validated tools. Medical records were reviewed for early disease variables and medication. RESULTS: By the PRINTO criteria, 31/59 (51%) patients were active and 29/59 (49%) were inactive. By MDAAT, 43/59 (73%) of the patients had measurable disease activity, most commonly found in the skin (59%) and skeletal (27%) systems. MDAAT showed moderate to strong correlations with other disease activity measures (rsp 0.39-0.87, P < 0.05) except for muscle enzymes. Active patients had higher disease activity than inactive patients measured by MDAAT (P < 0.001) and other disease characteristics (all P ≤ 0.002) except for patients' global assessment of disease activity. After controlling for gender and follow-up time, calcinosis during disease-course predicted high MDAAT, age<9 years at diagnosis predicted active disease and organ damage present 6-12 months post diagnosis predicted both outcomes. CONCLUSION: After 16.8 years, 51-73% of JDM patients had active disease. Disease activity by the PRINTO criteria and MDAAT were moderately to highly associated with most other disease characteristics and was predicted by early damage.
Authors: Takayuki Kishi; William Warren-Hicks; Nastaran Bayat; Ira N Targoff; Adam M Huber; Michael M Ward; Lisa G Rider Journal: Rheumatology (Oxford) Date: 2021-05-14 Impact factor: 7.580
Authors: Vladislav Tsaltskan; Annette Aldous; Sam Serafi; Anna Yakovleva; Heidi Sami; Gulnara Mamyrova; Ira N Targoff; Adam Schiffenbauer; Frederick W Miller; Samuel J Simmens; Rodolfo Curiel; Olcay Y Jones; Lisa G Rider Journal: Semin Arthritis Rheum Date: 2019-06-28 Impact factor: 5.532
Authors: Birgit Nomeland Witczak; Thomas Schwartz; Zoltan Barth; Eli Taraldsrud; May Brit Lund; Trond Mogens Aaløkken; Berit Flatø; Ivar Sjaastad; Helga Sanner Journal: Rheumatol Int Date: 2022-01-04 Impact factor: 3.580
Authors: Claire T Deakin; Shireena A Yasin; Stefania Simou; Katie A Arnold; Sarah L Tansley; Zoe E Betteridge; Neil J McHugh; Hemlata Varsani; Janice L Holton; Thomas S Jacques; Clarissa A Pilkington; Kiran Nistala; Lucy R Wedderburn Journal: Arthritis Rheumatol Date: 2016-10-09 Impact factor: 10.995